Menu Search
Equities

Neogenomics Inc

NG9:FRA

Neogenomics Inc

Actions
  • Price (EUR)14.50
  • Today's Change0.00 / 0.00%
  • Shares traded29.00
  • 1 Year change+18.85%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 07:02 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Neogenomics Inc grew revenues 16.07% from 509.73m to 591.64m while net income improved from a loss of 144.25m to a smaller loss of 87.97m.
Gross margin42.64%
Net profit margin-12.50%
Operating margin-15.17%
Return on assets-4.71%
Return on equity-8.39%
Return on investment-5.32%
More ▼

Cash flow in USDView more

In 2023, Neogenomics Inc increased its cash reserves by 30.13%, or 79.31m. Cash Flow from Investing totalled 76.71m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 1.95m for operations while cash generated from financing totalled 4.55m.
Cash flow per share-0.045
Price/Cash flow per share--
Book value per share7.16
Tangible book value per share0.2872
More ▼

Balance sheet in USDView more

Neogenomics Inc has a Debt to Total Capital ratio of 37.08%, a lower figure than the previous year's 56.14%.
Current ratio2.01
Quick ratio1.93
Total debt/total equity0.5892
Total debt/total capital0.3708
More ▼

Growth rates in USD

SmartText is unavailable
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		32.16
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.